Q3 2026 Insulet Corporation Earnings Call - INSULET CORP

Explicit Guidance:

• FY2026 Revenue Growth: Narrowed to the high end of prior range; constant currency growth expected at 21–22% for total company and 21.5–22.5% for total Omnipod (FX tailwind of ~100 bps).
• FY2026 Segment Revenue Growth:
  • U.S. Omnipod: 17.5–18.5% (driven by NCS growth, positive pricing, Q4 attrition/utilization similar to Q3).
  • International Omnipod: 32–33% on a constant currency basis (FX tailwind of ~300 bps; price-mix benefit contributed high single digits).
• Q4 2026 Revenue Growth (YoY Constant Currency): 13.5–17% total company; 13–16.5% total Omnipod.
• Q4 2026 Segment Growth: U.S. Omnipod 10–13.5%; International Omnipod 21–24% (reported FX headwind of ~50 bps).
• FY2026 Profitability: Adjusted operating margin expansion of ~150 bps; Adjusted operating margin expected at 22%; Net interest/other expense $40–45 million; Non-GAAP tax rate 20–20.5%; Shares outstanding ~70 million; Adjusted EPS growth >30%.
• FY2026 Cash Flow: Free cash flow expected at ~$275 million (offset by capex and working capital needs).
• FY2026 Capital Allocation: $400 million allocated to share repurchases in Q4.
• FY2027 Outlook (Preliminary): Total company growth expected modestly below mid-teens (down from prior Q2 "mid-teens" framework); U.S. growth expected at low end of prior range (9–14% framework, likely high single digits); International growth expected to moderate meaningfully from 2026 levels due to tough comps and reduced price-mix benefit.
• FY2027 EPS: Continued confidence in >25% EPS growth over the horizon (previously cited >20% for 2027).

Business-Segment Outlook:

• Product Launches:
  • Omnipod 6: Submitted final 510K; expected launch in 2027. Features 40% fewer boluses, improved time-in-range (76% in trials), and full international launch capability.
  • Freestyle Libre 3 Plus iOS: Limited market release expected in Q4 2026 in the U.S. to reach ~450,000 MDI users.
  • Omnipod Fully Closed-Loop for Type 2: Pivotal study enrollment complete; target 510K submission in 2027 with a planned launch in 2028.
  • Omnipod Discover: Full U.S. release achieved in October; early adoption >35,000 users/5,000 clinicians.
• Customer Base & Retention: Global customer base grew >20% YoY; Type 2 starts balanced with Type 1 (>40% of U.S. starts). Expected to see building impact on Type 2 retention and onboarding improvements in 2027 following Q3 "green shoots."
• International Expansion: Omnipod 5 in 20 markets; 80% of international customers expected to convert to Omnipod 5 by end of 2026. Recent launches in Spain; ongoing sensor integration expansion.

Market and Competitive Outlook:

• Competition: Expect a more dynamic competitive environment in 2027 as new entrants (patch pumps) launch; Insulet anticipates losing "a couple of share points" in new customer starts but maintaining leadership share.
• Market Dynamics: AID market remains under-penetrated vs. CGM; Insulet drives ~2/3 of category growth and sources ~90% of volume from MDI converts.
• Pricing: U.S. pricing expected to remain stable in 2027 following PBM contract renewals; International price-mix benefits expected to normalize as 80% of users transition to Omnipod 5.
• Demand Drivers: "Lifestyle fit," "quality of life," and "confidence" remain primary patient prescriber selection factors; AID market expected to expand despite new entrants.

Macro / Industry Outlook:

• Foreign Exchange: FX expected to contribute ~100 bps to total company growth in 2026 (Omnipod ~100 bps; International ~300 bps); ~50 bps headwind to international reported growth in Q4.
• Regulatory: 510K submissions on track for Omnipod 6 (2026/2027) and Type 2 closed-loop (2027); ADA guidelines recommending AID as standard of care continue to support category growth.
• GLP-1 Impact: No observed negative impact on Type 2 new customer starts; GLP-1s viewed as complementary to insulin therapy.

Strategic Initiatives:

• Sales Force & CRM: Completed U.S. sales force expansion (+25% footprint) and rolled out new CRM platform (first in 10 years) to improve targeting and message delivery.
• Type 2 Action Plan: Implemented stricter sample governance, added clinical retention specialists, and adjusted sales compensation to include retention metrics; early improvements in retention seen in Q3.
• Manufacturing & Supply: Multi-site network (Acton, Malaysia, Costa Rica) providing resiliency and capacity for tens of millions of pods; scale advantage expected to deter competitors initially.
• M&A/Capex: No new M&A mentioned; focus on organic capex to support inventory and manufacturing capacity for growth.

Risks and Headwinds to Outlook:

• Competitive Entry: New products entering the market in 2027 will increase price pressure and share erosion on new starts.
• Macroeconomic/Comps: Tougher year-over-year comparisons internationally in 2027 due to high 2026 performance; reduced price-mix benefits as base product mixes shift.
• Execution Risks: Timelines for Omnipod 6 and Type 2 closed-loop launches remain subject to regulatory timing; impact of new commercial initiatives (CRM, Type 2 retention) expected to build gradually over quarters.
• FX Volatility: Continued exposure to foreign exchange rates affecting reported growth.

Management Tone on the Future:

• Confidence Level: Highly confident in long-term growth and profitability; describes 2027 outlook as "conservative" and "thoughtful" rather than indicative of weakness.
• Strategic Shift: Moving from aggressive 20%+ growth assumptions to a "moderate" profile for 2027 to account for larger revenue base and competitive headwinds, while maintaining "top-tier" growth expectations.
• Differentiation: Emphasizes "unrivaled financial capacity," manufacturing scale, and data moats as durable competitive advantages that will secure a "disproportionate share" of new starts.

Miscellaneous:

• Shareholder Return: Board approved $1 billion increase in share repurchase authorization; $400 million to be deployed in Q4 2026.
• Liquidity: Revolver upsized to $750 million; cash and investments at $584 million at quarter end; free cash flow generation supporting both growth capex and capital returns.
• Data: Over 100 million automated dosing decisions and 850 million data messages processed daily, creating a significant real-world evidence dataset.